Short-acting somatostatin analogs can be used up to 24 hours before imaging with Ga 68 dotatate.Image patients with Ga 68 dotatate PET just prior to dosing with long-acting somatostatin analogs. Non-radioactive somatostatin analogs competitively bind to the same somatostatin receptors as Ga 68 dotatate.Post Marketing Experience: Nausea, vomiting, and injection site pain and burning sensation were all reported during post approval use.No serious adverse reactions were identified. Clinical Trials Experience: The safety of Ga 68 dotatate was evaluated in three single center studies and in a survey of the scientific literature.Uptake may need to be confirmed by histopathology or other assessments.thyroid disease or subacute inflammation) or might occur as a normal physiologic variant (e.g. Increased uptake might also be seen in other pathologic conditions (e.g.However, uptake can also be seen in a variety of other tumor types (e.g. The uptake of Ga 68 dotatate reflects the level of somatostatin receptor density in NETs.Drink and void frequently during the first hours following administration to reduce radiation exposure. Instruct patients to drink a sufficient amount of water to ensure adequate hydration prior to administration of Ga 68 dotatate.Ensure safe handling and preparation reconstitution procedures to protect patients and health care workers from unintentional radiation exposure.Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ga 68 dotatate contributes to a patient’s overall long-term cumulative radiation exposure.Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides.

Netspot logo